Affiliation:
1. Department of Pharmacology, Walter Reed Army Institute of Research, Washington, DC 20307-5100, USA.
Abstract
The crystal and molecular structures and absolute configuration of (-)-halofantrine hydrochloride were determined by X-ray diffraction. The absolute configuration of the single chiral center of (-)-halofantrine was established to be in the S configuration. Thus, (+)-halofantrine, the more cardiotoxic isomer, has the R configuration. The carbon atom adjacent to the aromatic ring has the same configuration in both (+)- halofantrine and quinidine, suggesting a stereospecific component to the cardiotoxicity produced by both agents. The intramolecular N ... O distance is 4.177 +/- 0.006 A (1 A = 0.1 nm), which is close to the N ... O distance found in the crystal structure of (+/-)-halofantrine hydrochloride, even though the N-H group points in opposite directions in racemic halofantrine and (-)-halofantrine. Both the hydroxyl group and the amine group form hydrogen bonds with the chloride anions. The crystallographic parameters for (-)-halofantrine hydrochloride were as follows: chemical formula, C26H31Cl2F6NO+. Cl-; Mr, 492.4; symmetry of unit cell, orthorhombic; space group, P2(1)2(1)2(1); parameters of unit cell, a was 6.290 +/- 0.001 A, b was 13.533 +/- 0.003 A, and c was 30.936 +/- 0.006 A; volume of the unit cell, 2,633.2 +/- 0.7 A(3); number of molecules per unit cell, 4; calculated density, 1.354 g cm(-3); source of radiation, Cu K(alpha) (lambda = 1.54178 A); mu (absorption coefficient), 3.50 mm(-1); F(000) (sum of atomic scattering factors at zero scattering angle), 1,120; room temperature was used; final R (residual index), 4.75% for 2,988 reflections, with absolute value of Fo > 3sigma(F), where Fo is the observed structure factor and F is the structure factor.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference23 articles.
1. In vitro activity of the enantiomers of mefloquine, halofantrine, and enpiroline against Plasmodium falciparum;Basco L. K.;Br. J. Clin. Pharmacol.,1992
2. Malaria: treatment efficacy of halofantrine (WR 171,669) in initial field trials;Boudreau E. F.;Thailand. Bull. W. H. O.,1988
3. Halofantrine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic potential;Bryson H. M.;Drugs,1992
4. Resolution of antimalarial agents via complex formation with ~-(2,4,5,7-tetranitro-9-fluorenylideneaminooxy)propionic acid;Carroll F. I.;J. Med. Chem.,1978
5. Plasma concentrations of the enantiomers of halofantrine and its main metabolite in malaria patients;Gimenez F.;Eur. J. Clin. Pharmacol.,1994
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献